ResultsIQ

ResultsIQ › Latest results › Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited Q4 FY25 earnings call summary

NSE: VIJAYA · BSE: 543350

Earnings call of 12 May 2025, summarised by AI from the filing.

Vijaya Diagnostic Q4 FY25 revenue ₹173 cr, EBITDA margin 39.8%; guides 15%+ CAGR for next 2-3 years with 1-2% FY26 margin drag from new hubs.

Key takeaways

  1. Guidance 15% plus CAGR for next 2-3 years; FY26 EBITDA margin drag of 1-2%.
  2. Expansion 6 hubs launched in last 2 months; 5 more planned in FY26.
  3. Margin risk Gross margin pressure from higher wellness share and input cost increase.

Original filing on BSE

Vijaya Diagnostic Centre Limited Q1 FY27 results

As filed: Revenue ₹231 cr (+23% year on year), EBITDA ₹98.5 cr (+35% year on year), PAT ₹53.1 cr (+36% year on year), EBITDA margin 42.7% (+383 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹219 cr (+27% year on year), EBITDA ₹95.5 cr (+40% year on year), PAT ₹47.9 cr (+37% year on year), EBITDA margin 43.5% (+423 bps). Score 88 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 423 bps year on year. Revenue rose ₹46.4 cr on a year ago, more than the ₹18.0 cr it added the year before. Share price after the results: +17.5% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹205 cr (+21% year on year), EBITDA ₹86.1 cr (+28% year on year), PAT ₹43.2 cr (+23% year on year), EBITDA margin 41.9% (+229 bps). Score 64 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 229 bps year on year. Revenue rose ₹36.2 cr on a year ago, more than the ₹36.0 cr it added the year before. Share price after the results: −0.3% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹202 cr (+10% year on year), EBITDA ₹82.0 cr (+9% year on year), PAT ₹43.0 cr (+2% year on year), EBITDA margin 40.6% (−39 bps). Score 26 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 39 bps year on year. Revenue rose ₹19.0 cr on a year ago, against ₹44.0 cr the year before. Share price after the results: −0.2% in 30 days (Nifty 500: +0.5%).
  • Q1 FY26: Revenue ₹188 cr (+21% year on year), EBITDA ₹73.0 cr (+20% year on year), PAT ₹39.0 cr (+22% year on year), EBITDA margin 38.8% (−27 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin fell 27 bps year on year. Revenue rose ₹32.0 cr on a year ago, against ₹35.0 cr the year before. Share price after the results: +0.7% in 27 days (Nifty 500: −3.2%).
  • Q4 FY25: Revenue ₹173 cr (+12% year on year), EBITDA ₹68.0 cr (+8% year on year), PAT ₹35.0 cr (+3% year on year), EBITDA margin 39.3% (−134 bps). Score 23 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 134 bps year on year. Revenue rose ₹18.0 cr on a year ago, against ₹34.0 cr the year before. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹169 cr (+27% year on year), EBITDA ₹67.0 cr (+26% year on year), PAT ₹35.0 cr (+35% year on year), EBITDA margin 39.6% (−20 bps). Score 72 of 100, Above trend. EBITDA margin fell 20 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter.
  • Q2 FY25: Revenue ₹183 cr (+32% year on year), EBITDA ₹75.0 cr (+29% year on year), PAT ₹42.0 cr (+24% year on year), EBITDA margin 41.0% (−74 bps). Score 71 of 100, Above trend. EBITDA margin fell 74 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Vijaya Diagnostic Centre Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.